{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:13:39Z","timestamp":1792487619012,"version":"4.5.0"},"reference-count":100,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitors (ICI) are a core mainstay of cancer care. In routine practice, the Time of Day of Administration (ToDA) of ICIs invariably is not stipulated in the clinical notes. Thus, treatment timing of administration is mainly dictated by constraints related to the organization and planning of the outpatient infusion centers, the clinical pharmacy, which reconstitutes the parenteral drugs, and the patients themselves. A growing body of evidence, recently including a prospective randomized trial, has shown a significant halving of risk reduction of an earlier death by early rather than late ToDA of ICIs in patients with 10 different advanced cancer primaries. The ToDA-dependent effect was found irrespective of the ICI type, and its use as a single agent or in combination. Similar favorable impact of early ToDA has been found on pharmacologic or clinical outcomes for a range of immunomodulated therapies including vaccines, chimeric antigen receptor T cells, and allo-HSCT. Physiologic mechanisms underpinning these clinical observations involve circadian (ie, of about a day) changes in immune cell trafficking and functions, altogether making the adaptive branch of the immune system more susceptible to pharmacologic intervention in the morning. Here, we critically discuss the available evidence, the knowledge gaps, and the impediments to deliver time-stipulated ICI in progressively busier cancer outpatient infusion centers. With numerous retrospective studies involving over 8,000 patients, we discuss consistencies and heterogeneities in these reports, including cutoff times associated with clinical benefit. We appraise the provision of care, particularly focusing on the workflows of the cancer outpatient infusion centers and the clinical pharmacy. Additionally, we propose here some practical quality improvement approaches to make morning ToDA of ICIs feasible in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-25-00661","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T20:59:14Z","timestamp":1765832354000},"page":"913-923","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":6,"title":["Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration"],"prefix":"10.1200","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0653-8261","authenticated-orcid":true,"given":"Pasquale F.","family":"Innominato","sequence":"first","affiliation":[{"name":"North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, UK"},{"name":"Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0967-1276","authenticated-orcid":true,"given":"Thierry","family":"Landr\u00e9","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Universitaires Paris-Seine-Saint-Denis, H\u00f4pital Ren\u00e9 Muret, Assistance Publique-H\u00f4pitaux de Paris, Sevran, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2074-2557","authenticated-orcid":true,"given":"Abdoulaye","family":"Karabou\u00e9","sequence":"additional","affiliation":[{"name":"UPR \u201cChronotherapy, Cancer and Transplantation\u201d, Medical School, Paris-Saclay University, Villejuif, France"},{"name":"Medical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-2983","authenticated-orcid":true,"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[{"name":"UPR \u201cChronotherapy, Cancer and Transplantation\u201d, Medical School, Paris-Saclay University, Villejuif, France"},{"name":"Thoracic and Medical Oncology Unit, Avicenne Hospital, Assistance Publique-H\u00f4pitaux de Paris, Bobigny, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Buchwald","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-7176","authenticated-orcid":true,"given":"Yongchang C.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Griffiths","sequence":"additional","affiliation":[{"name":"North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":true,"given":"Christos","family":"Choua\u00efd","sequence":"additional","affiliation":[{"name":"Service de Pneumologie, Centre Hospitalier Intercommunal de Cr\u00e9teil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1364-7463","authenticated-orcid":true,"given":"Francis A.","family":"L\u00e9vi","sequence":"additional","affiliation":[{"name":"Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, UK"},{"name":"UPR \u201cChronotherapy, Cancer and Transplantation\u201d, Medical School, Paris-Saclay University, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-016-1610-1"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104529"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2007.04324.x"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.11.016"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211066500"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19074265"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33422"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00546-5"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105141"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27825"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010644"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1802337"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991773302"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb0738"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00639-2"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.116.013441"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2356167"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.07.002"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.11.030"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050732"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02704-9"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-090122-050842"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200516"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175706"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102220"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113571"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100659"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251339921"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.457"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106761"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14596"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1120"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105607"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.01.007"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1352"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040896"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e21126"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-023-01006-y"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2025.103371"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050898"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.681"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008011"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1851"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9542"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.616"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1512972"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0139"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2662"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e16541"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13897"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.705"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-571"},{"key":"e_1_3_6_55_2","first-page":"S705-6","article-title":"1063P influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort","volume":"35","author":"Albarr\u00e1n FV","year":"2024","unstructured":"Albarr\u00e1n FV, Rosero Rodriguez DI, Chamorro-Perez J, et al: 1063P influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort. Ann Oncol Sept 35:S705-6, 2024","journal-title":"Ann Oncol Sept"},{"key":"e_1_3_6_56_2","first-page":"S1558","article-title":"Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma","author":"Dizman N","year":"2023","unstructured":"Dizman N, Govindarajan A, Zengin ZB, et al: Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma. Clin Genitourin Cancer:S1558-S7673, 2023","journal-title":"Clin Genitourin Cancer"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16537"},{"key":"e_1_3_6_58_2","article-title":"Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer","volume":"43","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Huang Z, Zeng L, et al: Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer. J Clin Oncol 43, 2025 (suppl 16; abstr 8516)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS9601"},{"key":"e_1_3_6_60_2","article-title":"Diurnal rhythms in chimeric antigen receptor T cell performance: An observational study of 670 patients","author":"Lyons PG","unstructured":"Lyons PG, Gill E, Kumar P, et al: Diurnal rhythms in chimeric antigen receptor T cell performance: An observational study of 670 patients. medRxiv 10.1101\/2025.05.15.25327612","journal-title":"medRxiv"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.03.022"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.08.009"},{"key":"e_1_3_6_63_2","first-page":"100815","article-title":"Primary results from IMscin002: A study to evaluate patient preferences and perceptions of health care professionals for atezolizumab subcutaneous versus intravenous for the treatment of NSCLC","volume":"6","author":"Cappuzzo F","year":"2025","unstructured":"Cappuzzo F, Zvirbule Z, Korbenfeld E, et al: Primary results from IMscin002: A study to evaluate patient preferences and perceptions of health care professionals for atezolizumab subcutaneous versus intravenous for the treatment of NSCLC. JTO Clin Res Rep 6:100815, 2025","journal-title":"JTO Clin Res Rep"},{"key":"e_1_3_6_64_2","first-page":"246","article-title":"Prolonged in-use stability of diluted atezolizumab in commercial intravenous bags","volume":"25","author":"Hui A","year":"2021","unstructured":"Hui A, Yin J, Liu W, et al: Prolonged in-use stability of diluted atezolizumab in commercial intravenous bags. Int J Pharm Compd 25:246-257, 2021","journal-title":"Int J Pharm Compd"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.06.014"},{"key":"e_1_3_6_66_2","first-page":"192","article-title":"Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion","volume":"135","author":"Le GG","year":"2020","unstructured":"Le GG, Vieillard V, Mouraud S, et al: Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion. Eur J Cancer Oxf Engl 135:192-202, 2020","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy13010022"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.01.008"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115373"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164767"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0319"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00009-2"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102559"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219839445"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2007.07.005"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.1177\/07487304221131114"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2014.916990"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.add0846"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-051920-095416"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00680-z"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.3390\/biology8030054"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102633"},{"key":"e_1_3_6_83_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1284089"},{"key":"e_1_3_6_84_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240284"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.04.015"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115748"},{"key":"e_1_3_6_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e12616"},{"key":"e_1_3_6_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.009"},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.002"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells12162068"},{"key":"e_1_3_6_91_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1402837"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200239"},{"key":"e_1_3_6_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00023-7"},{"key":"e_1_3_6_94_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw691"},{"key":"e_1_3_6_95_2","first-page":"e82994","article-title":"The importance of timing in immunotherapy: A systematic review","volume":"17","author":"Nagy S","year":"2025","unstructured":"Nagy S, Hussein A, Kesselman MM: The importance of timing in immunotherapy: A systematic review. Cureus 17:e82994, 2025","journal-title":"Cureus"},{"key":"e_1_3_6_96_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081095"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403108"},{"key":"e_1_3_6_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01832-4"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2024.33.Sup17.S1"},{"key":"e_1_3_6_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.006"},{"key":"e_1_3_6_101_2","first-page":"205520762311974","article-title":"Using video consultations for clinical assessment and decision of treatment readiness before chemotherapy: A mixed-methods study among patients with gastrointestinal cancer and oncology nurses","volume":"9","author":"Dieperink KB","year":"2023","unstructured":"Dieperink KB, Vestergaard LV, M\u00f8ller PK, et al: Using video consultations for clinical assessment and decision of treatment readiness before chemotherapy: A mixed-methods study among patients with gastrointestinal cancer and oncology nurses. Digit Health 9:20552076231197415, 2023","journal-title":"Digit Health"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:01:25Z","timestamp":1781647285000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/OP-25-00661"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00661","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}